Streetbeat News

GSGTF

GenSight Biologics S.A.

http://www.gensight-biologics.com/

CEO

Bernard Gilly

Industry

Biological Product (except Diagnostic) Manufacturing

Open

0.48

Mkt cap

31M

Volume

756

High

0.48

P/E Ratio

-0.63

52-wk high

0.48

Low

0.24

Div yield

N/A

52-wk low

0.24

GenSight Biologics reported a cash position of €0.9 million as of March 31, 2025, which is insufficient to cover operational requirements for the next 12 months. The company is actively pursuing fundraising activities to extend its cash runway, initiate the RECOVER Phase III clinical trial, and prepare a UK marketing application for LUMEVOQ®. Management is exploring debt, equity, and potential partnership opportunities to secure financial stability.

Portfolio Pulse from

April 07, 2025 | 6:30 pm

GenSight Biologics reported a cash position of €0.9 million as of March 31, 2025, which is insufficient to cover operational requirements for the next 12 months. The company is actively pursuing fundraising activities to extend its cash runway, initiate the RECOVER Phase III clinical trial, and prepare a UK marketing application for LUMEVOQ®. The company is exploring debt, equity, and potential partnership opportunities to secure its financial future.

Portfolio Pulse from

April 07, 2025 | 6:30 pm

GenSight Biologics will present new scientific data on its gene therapy LUMEVOQ® at the NANOS 2025 meeting in Tucson, Arizona. This update is significant for the company's focus on retinal neurodegenerative diseases.

Portfolio Pulse from

March 17, 2025 | 6:45 am

GenSight Biologics, a biopharma company, reported its cash position as of December 31, 2024, and provided a business update. The company has secured bridge financing to enhance operational flexibility.

Portfolio Pulse from

January 23, 2025 | 6:00 pm

GenSight Biologics has submitted an updated regulatory file for its LUMEVOQ® gene therapy to the French agency ANSM, aiming to restart its Early Access Program in France.

Portfolio Pulse from

November 13, 2024 | 7:00 am

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.